Monte Rosa Therapeutics, Inc. — Q2 2023 Form 10-Q
Reporting period: Three and six months ended June 30, 2023. Unaudited consolidated financial statements. Monte Rosa is a pre-commercial biotechnology company developing molecular glue degraders (MGDs) using its QuEEN platform. Its programs include MRT-2359 (GSPT1), in clinical development, and MRT-6160 (VAV1), in IND-enabling work.
Financial results and position
Amounts are in millions of U.S. dollars unless otherwise stated. The filing presents no product revenue; it reports operating expenses and losses, so revenue margins are not applicable.
| Metric | Q2 2023 | Q2 2022 | Six months 2023 | Six months 2022 |
|---|---|---|---|---|
| Research and development expense | $29.1 | $20.9 | $55.8 | $38.9 |
| General and administrative expense | $8.1 | $6.3 | $15.6 | $12.7 |
| Total operating expenses | $37.2 | $27.2 | $71.5 | $51.5 |
| Net loss | $35.2 | $26.5 | $67.2 | $50.4 |
| Net loss per share | $0.71 | $0.57 | $1.36 | $1.08 |
| Operating cash used | — | — | $48.7 | $47.9 |
- At June 30, cash and cash equivalents were $47.0 million, marketable securities $156.0 million, and restricted cash $4.5 million: $207.6 million combined. The company separately cited $203.1 million in cash, cash equivalents and marketable securities, excluding restricted cash.
- Total assets were $278.6 million; stockholders’ equity was $213.7 million. The company reported no credit facility or committed capital source and no debt balance in the presented balance sheet. Operating lease liabilities totaled $47.0 million, including $2.7 million current; undiscounted future minimum lease payments were $72.4 million.
- Six-month investing cash flow was positive $38.9 million, reflecting marketable-security maturities and sales, partly offset by purchases and $15.7 million of property and equipment. Financing cash flow was $1.2 million, primarily employee equity-plan proceeds.
Changes versus comparable periods
- Q2 operating expenses increased $10.0 million year over year; net loss increased $8.7 million. For the first six months, operating expenses rose $19.9 million and net loss rose $16.8 million.
- Management attributed higher R&D spending chiefly to expanded research activity, increased headcount and facilities, and related laboratory costs. R&D staff increased to 107 from 85 year over year; G&A staff increased to 26 from 19.
- Interest income rose to $2.3 million in Q2 and $4.7 million for the half year, primarily due to higher interest rates on investments. The company recorded a $0.2 million income-tax provision in the first half of 2023, versus none in the prior-year period.
- Property and equipment purchases were $15.7 million in the first half, versus $4.2 million a year earlier. The company also expanded its Basel lease space in April 2023.
Outlook, risks and notable items
- Management expects operating losses, negative operating cash flow, and R&D and G&A spending to continue increasing as it advances candidates and clinical and preclinical work. It estimates current cash, cash equivalents and marketable securities will fund operating expenses and capital requirements for at least 12 months from issuance of the interim financial statements; this estimate depends on assumptions that may prove incorrect.
- Additional financing will be needed for future research and development. Equity financing could dilute stockholders; debt or other financing may not be available on acceptable terms. Failure to obtain funding could require delaying, reducing or ending programs.
- Development and regulatory approval remain uncertain; the company identifies clinical, preclinical, manufacturing, hiring, intellectual-property, competition and commercialization risks. It has no commercial products and its accumulated deficit was $297.8 million.
- A license and collaboration agreement may require milestone payments of up to $7 million for a covered first product and $3.5 million for each covered subsequent product, plus low-single-digit royalties if covered products are commercialized. The filing reports no activity under the agreement in the first half.
- The company reported no material litigation and no off-balance-sheet arrangements. Its $100 million at-the-market offering facility remained available; no shares were sold under it in the first half of 2023.
- After quarter-end, CFO Ajim Tamboli resigned effective August 8, 2023. CEO Markus Warmuth assumed principal financial officer duties, and VP Corporate Controller Edmund Dunn assumed principal accounting officer duties. The filing says the resignation was not related to a disagreement with the company.
Important facts for investors to verify
- Whether the stated 12-month funding runway remains appropriate under updated spending, trial, facility and capital-expenditure plans.
- Clinical progress, enrollment and timing of data for MRT-2359, and milestones for MRT-6160 and other pipeline programs.
- Future R&D spending and cash burn, including the effects of laboratory expansion and lease commitments.
- Availability and terms of additional financing, including potential use of the ATM facility and resulting dilution.
- Continuity of financial reporting and controls following the CFO transition, and any subsequent changes to management’s outlook or risks.